SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

Alpha DaRT

DRTS·Alpha Tau Medical Ltd.
BULLISH
Drug Impact Rating5/10
Trial phase
Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to market
The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
Why 5/10
The next hard, dated catalyst is the Q3 2026 earnings call on November 24, 2026, which may include pipeline updates. The REGAIN interim data was just released (Nov 15) and the investor call is Nov 16. The IMPACT pancreatic study data is expected in early 2027 (no specific date). The PMA for cSCC is a modular submission without a specific PDUFA date. With no single make-or-break binary catalyst on a specific date in the next ~6 months, the impact score is capped at 5.
Actionable Insight BULLISH

The REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

Price Chart

Loading chart...

Executive Summary

Alpha Tau Medical (NASDAQ: DRTS) is developing Alpha DaRT, a novel alpha-radiation cancer therapy that delivers radium-224 sources directly into solid tumors. The company has generated strong early clinical data across multiple indications. On Nov 15, 2026, it announced that all 8 treated patients in its REGAIN glioblastoma trial remain alive with median survival not reached at 6.9 months follow-up. The ReSTART pivotal trial for recurrent cutaneous squamous cell carcinoma (cSCC) completed enrollment of 88 patients in May 2026, and the first PMA module was submitted to the FDA in January 2026. A head and neck cancer combo study with Keytruda showed a 100% objective response rate. The stock trades at $13.35 with a strong analyst consensus (9 analysts: 4 Strong Buy, 5 Buy, 2 Hold) and a mean price target of $20.60, implying 54% upside. The company had approximately $104.8 million in cash as of late August 2026.

How It Works

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is a novel cancer treatment that delivers a tiny source of radioactive material (radium-224) directly into a solid tumor. As the radium decays, it releases short-lived, high-energy alpha particles that diffuse through the tumor and destroy cancer cells from within, while sparing most of the surrounding healthy tissue. Alpha particles are much more powerful at killing cells than the X-rays used in standard radiation therapy, but they travel only a very short distance, making this a highly targeted treatment.

Trial Status

The ReSTART pivotal trial for recurrent cSCC (88 patients) completed enrollment in May 2026; the first PMA module was submitted to the FDA in January 2026. The REGAIN glioblastoma pilot trial was expanded from 10 to 20 patients by FDA in October 2026; interim data on 8 patients showed all alive with median survival not reached at 6.9 months. The IMPACT pancreatic cancer pilot study (48 patients) completed enrollment in August 2026 with initial data expected in early 2027. The ADMIRE study for immunocompromised cSCC patients is ongoing. A head and neck cancer combo study with Keytruda showed a 100% ORR in 9 evaluable patients.

The Two-Sided Case

▲ Bull Case1
All 8 treated patients in the REGAIN glioblastoma trial remain alive as of Nov 11, 2026, with median overall survival not yet reached at 6.9 months median follow-up, a striking early signal in a uniformly fatal disease. The ReSTART pivotal trial for recurrent cSCC completed enrollment of 88 patients in May 2026, and the first PMA module was submitted to the FDA in January 2026, advancing toward a potential US approval. The head and neck cancer combo study with Keytruda showed a 100% objective response rate (9 evaluable patients) and 18.2-month median overall survival. Analyst consensus is strongly bullish: 4 Strong Buy, 5 Buy, 2 Hold, with a mean price target of $20.60 (54% upside from $13.38). Piper Sandler upgraded to Overweight on Nov 11, 2026, citing a catalyst-rich period. BlackRock doubled its position and UBS added in Q3 2026.
▼ Bear Case1
Alpha DaRT has no FDA approval in the US; the only marketing approvals are in Japan (head and neck cancer) and Israel (SCC of skin and oral cavity), leaving a long and uncertain regulatory path. The REGAIN glioblastoma trial is a small single-arm pilot study (up to 20 patients) that may not support registration. The company is pre-revenue and has accumulated significant losses; while cash was ~$104.8M as of late August 2026, the burn rate may require future dilution. The CFO sold shares (2,871 shares at ~$15, Aug 2026) under a 10b5-1 plan, and several institutional holders trimmed or exited positions in Q3 2026.

Upcoming Catalysts

  • Investor call to discuss REGAIN interim data on Nov 16, 2026
  • Q3 2026 earnings report on Nov 24, 2026
  • IMPACT pancreatic cancer pilot study initial data expected early 2027
  • Continued PMA modular submissions for cSCC (no specific dates announced)
  • Potential enrollment updates for expanded REGAIN glioblastoma trial

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Alpha Tau Medical Ltd. Press Release DRTS ·Originating report

Sources · 11

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 msn.com4 marketwatch.com5 nasdaq.com6 markets.financialcontent.com7 markets.businessinsider.com8 nasdaq.com9 marketscreener.com10 ad-hoc-news.de11 sec.gov